

## Expanded CRISPR/CAS9 Strategic Alliance

"Together with genOway, we desire to make available the best research models to pharmaceutical and biotech industries as well as academic laboratories, to best accelerate their research, shorten drug development timelines to enable such researchers to develop solutions for previously untreatable diseases in faster and more targeted ways."

Sigma-Aldrich® Lab and Production Materials and genOway, the leading company in the preclinical research model space, announced a new structure to a 2018 strategic alliance in the CRISPR/Cas9 field.


- genOway will continue leading the commercialization of the Sigma-Aldrich® CRISPR patent portfolio in the field of rodent animals, which includes the creation of genetically modified rodent animals and all rodent cells derived from these genetically modified rodent animals, and the genetic manipulation of rodent embryonic stem cells and rodent embryos to create genetically modified rodent animals. genOway has worldwide exclusivity in that area, which covers all commercial applications and includes the rights to sublicense to third parties for all business areas.
- We will lead the commercialization of the Sigma-Aldrich® CRISPR patent portfolio, including products and services, outside the field of rodent animals and in particular in the field of mammalian cells, including the sublicensing of rights to third parties for all business areas. genOway has however also been granted extended non-exclusive rights complementary to those in the field of rodent animals so that genOway can offer products and services for research applications on all mammalian cells, including rodent cells. For example, genOway clients

can perform research studies, sell preclinical services or distribute products using the products or services purchased from genOway.

- Both companies will collaborate to offer "one-stop shop" CRISPR sublicensing solutions, providing Sigma-Aldrich® CRISPR IP rights for both mammalian cells and the rodent animal field.

"CRISPR technology is a core competency of the Sigma-Aldrich® portfolio, which has 17 years' experience with providing genome editing research tools, spanning discovery to manufacturing. Together with genOway, we desire to make available the best research models to pharmaceutical and biotech industries as well as academic laboratories, to best accelerate their research, shorten drug development timelines to enable such researchers to develop solutions for previously untreatable diseases in faster and more targeted ways. We will continue to play an active role, responsibly and ethically, in ensuring that scientists have access to the Sigma-Aldrich® CRISPR technologies. This improved collaboration will ease the access to Sigma-Aldrich® CRISPR technologies and increase the value created by our licensing relationships," says Christopher Arnot, Director Business Development and Licensing, Gene Editing & Novel Modalities supporting the Sigma-Aldrich® portfolio.

"Sigma-Aldrich® CRISPR technologies are essential tools for the development of highly valuable preclinical models, and the Sigma-Aldrich® IP portfolio has become central to CRISPR/Cas9-based eukaryotic genome-editing applications. This improved alliance should enable genOway and the Sigma-Aldrich® portfolio to better serve clients and consequently strongly support innovation in the preclinical field," says Alexandre Fraichard, CEO of genOway.



The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the vibrant M, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

07/2022